

Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

Miltenyi Biotec

RRID:SCR_008984

Type: Tool

Proper Citation

Miltenyi Biotec (RRID:SCR_008984)

Resource Information

URL: <http://www.miltenyibiotec.com/en/>

Proper Citation: Miltenyi Biotec (RRID:SCR_008984)

Description: An Organization portal, Antibody supplier, Service resource,

Synonyms: Miltenyi Biotec Inc., Miltenyi Biotec GmbH

Resource Type: commercial organization

Keywords: biotechnology, biomedical, cellular therapy, cell isolation, flow cytometry, sample preparation, cell culture, molecular analysis, clinical application, small animal imaging

Resource Name: Miltenyi Biotec

Resource ID: SCR_008984

Alternate IDs: grid.59409.31, nlx_152412, Wikidata: Q1671300, Crossref funder ID: 501100004176, ISNI: 0000 0004 0552 5033

Alternate URLs: <https://ror.org/00qhe6a56>

Record Creation Time: 20220129T080250+0000

Record Last Update: 20260905T132631+0000

Ratings and Alerts

No rating or validation information has been found for Miltenyi Biotec.

No alerts have been found for Miltenyi Biotec.

Data and Source Information

Usage and Citation Metrics

We found 21314 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Spalato Ceruso M, et al. (2026) Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1887.

Chen K, et al. (2026) Identification of a distinct cluster of LY6E+ macrophages in esophageal squamous cell carcinoma: functional phenotype, spatial interaction, and prognostic significance. *British journal of cancer*, 135(3), 382.

Bui TM, et al. (2026) Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. *Cancer cell*, 44(6), 1179.

Sandoval TA, et al. (2026) Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. *Cancer research*, 86(7), 1639.

Neumann MA, et al. (2026) Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review. *Journal of comparative effectiveness research*, 15(7), e260033.

Chen Y, et al. (2025) A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia. *Cancer research*, 85(14), 2753.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. *Molecular cancer therapeutics*, 24(6), 843.

Choe M, et al. (2025) Preclinical Evaluation of Folate Receptor-? Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma. *Cancer research communications*, 5(9), 1701.

Xu SX, et al. (2025) Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2-Positive Solid Tumors. *Cancer immunology research*, 13(1), 35.

Lingel H, et al. (2025) SLAMF7 (CD319) on activated CD8+ T cells transduces environmental cues to initiate cytotoxic effector cell responses. *Cell death and differentiation*, 32(3), 561.

Nicolussi P, et al. (2025) Biocompatibility of Water-Dispersible Pristine Graphene and Graphene Oxide Using a Close-to-Human Animal Model: A Pilot Study on Swine. *Advanced healthcare materials*, 14(10), e2401783.

Lu X, et al. (2025) Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy. *Bioactive materials*, 43, 255.

Choi SH, et al. (2025) Piezo1 restrains proinflammatory response but is essential in T-cell-mediated immunopathology. *Journal of leukocyte biology*, 117(3).

Fan NW, et al. (2025) Activation of β_2 /2C adrenergic receptor ameliorates ocular surface inflammation through enhancing regulatory T cell function. *Mucosal immunology*, 18(1), 176.

Timilsina S, et al. (2025) Methods for assessing and removing non-specific photoimmunotherapy damage in patient-derived tumor cell culture models. *Photochemistry and photobiology*, 101(1), 4.

Zou Q, et al. (2025) Photo-metallo-immunotherapy: Fabricating Chromium-Based Nanocomposites to Enhance CAR-T Cell Infiltration and Cytotoxicity against Solid Tumors. *Advanced materials (Deerfield Beach, Fla.)*, 37(2), e2407425.

Huang C, et al. (2025) Tolerogenic dendritic cell-mediated regulatory T cell differentiation by Chinese herbal formulation attenuates colitis progression. *Journal of advanced research*, 70, 499.

Ferreira N, et al. (2025) OrganoidNet: a deep learning tool for identification of therapeutic effects in PDAC organoid-PBMC co-cultures from time-resolved imaging data. *Cellular oncology (Dordrecht, Netherlands)*, 48(1), 101.

Molina PA, et al. (2025) Aryl Hydrocarbon Receptor Activation Promotes Effector CD4⁺ T Cell Homeostasis and Restrains Salt-Sensitive Hypertension. *Function (Oxford, England)*, 6(2).

Yablonska S, et al. (2025) Regulation of Mutant Huntingtin Mitochondrial Toxicity by Phosphomimetic Mutations within Its N-Terminal Region. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 45(8).